Atlas Trials

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Clinical trial NCT04603365 · WITHDRAWN

Trial details

NCT number
NCT04603365
Sponsor
Jonsson Comprehensive Cancer Center
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Clear Cell Papillary Renal NeoplasmCollecting Duct CarcinomaHereditary Leiomyomatosis and Renal Cell CarcinomaHereditary Papillary Renal Cell CarcinomaMetastatic Renal Cell CarcinomaMetastatic Unclassified Renal Cell CarcinomaPapillary Renal Cell CarcinomaStage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8Stage IV Renal Cell Cancer AJCC v8Tubulocystic Renal Cell CarcinomaUnresectable Renal Cell Carcinoma
Start date
2021-10-18
Primary completion
2023-05-07
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.